1. Meta-analysis of the prognostic value of abnormally expressed lncRNAs in hepatocellular carcinoma
- Author
-
Qu Z, Yuan CH, Yin CQ, Guan Q, Chen H, and Wang FB
- Subjects
disease-free survival ,Overall survival (OS) ,Relapse-free survival (RFS) ,HCC ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,Key words lncRNA - Abstract
Zhen Qu,1,* Chun-Hui Yuan,2,* Chang-Qing Yin,1 Qing Guan,2 Hao Chen,1 Fu-Bing Wang1 1Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, 2Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, People’s Republic of China *These authors contributed equally tothis work Abstract: Many long noncoding RNAs (lncRNAs) have been reported to be abnormally expressed in hepatocellular carcinoma (HCC), and may have the potential to serve as prognostic markers. In this study, a meta-analysis was conducted to systematically evaluate the prognostic value of various lncRNAs in HCC. Eligible literatures were systematically collected from PubMed, Embase, Web of Science, and Cochrane Library (up to December 30, 2015). The main outcomes including overall survival, relapse-free survival, and disease-free survival were analyzed. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated using random- or fixed-effects models. A total of 2,991 patients with HCC in People’s Republic of China from 27 studies were included in the analysis. The level of lncRNAs showed a significant association with clinical outcomes. Abnormally elevated lncRNA transcription level predicted poor overall survival (HR: 1.68, 95% CI: 1.20–2.34, P=0.002; I2=75.5%, P=0.000) and relapse-free survival (HR: 2.08, 95% CI: 1.65–2.61, P
- Published
- 2016